Hello. I’m Chris, and I am a health economist.
Mostly, I work on research relating to the methods and application of cost-effectiveness analysis and the measurement of health-related quality of life.
I also eat plants, run marathons, and listen to punk rock.
You might know me as:
- Director of Tertium Research
- Honorary Associate Professor at the University of Nottingham
- Founder and editor-in-chief at The Academic Health Economists’ Blog
- Webmaster for HESG
- A member of the EuroQol Group (and the Descriptive Systems Working Group)
Contact / Newsletter
I don’t really use social media nowadays. Can we keep in touch by email? Enter yours in the box below and I’ll update you about new research, conference and travel plans, and other happenings.
If you’d just like to contact me, please enter your email address in the box below and hit the button. You’ll receive an email to which you can reply. You won’t be added to the newsletter unless you choose to be.
All my stuff
Here is my attempt to list all of the stuff I’ve produced that someone somewhere might like to see. It’s a work in progress. Please let me know if you can’t find what you’re looking for or if you find errors.
Filter by Type
09 December 2025
British Journal of Clinical Pharmacology
13 November 2025
Journal of Health Economics and Outcomes Research
12 February 2025
Value in Health
23 November 2024
Quality of Life Research
September 2024
Health Economics
15 April 2024
Value in Health
2024
Value in Health
31 October 2023
Value in Health
2024
A framework for value-aligned pricing of combination therapies
OHE Contract Research Report
2023
Programme Grants for Applied Research
2023
Frontiers in Health Services
2023
The case for expanding uptake of next-generation sequencing for lung cancer in Europe
OHE Contract Research Report
2023
Do we need animal health economics?
Health Economists’ Study Group, University of Manchester
2022
Applied Health Economics and Health Policy
2022
BJGP Open
2022
Quality of Life Research
2022
Value in Health
2022
The basis for a new framework to determine the cost-effectiveness threshold
ISPOR Europe
2022
The value of next generation sequencing for lung cancer in Europe: findings from a literature review
ISPOR Europe
2021
Medical Decision Making
2021
F1000 Research
2021
MedRxiv
2021
Supply-side cost-effectiveness thresholds: questions for evidence-based policy
HTAi Annual Meeting
2021
Supply-side cost-effectiveness thresholds: one name, many faces?
HTAi Annual Meeting
2021
Drop Dead: is it time to remove ‘dead’ from health state valuation?
ISPOR Virtual Conference
2021
Sleepio: real-world evaluation and NICE assessment of a digital health technology
Network of Alberta Health Economists Rounds
2020
In: Arnold, R.J.G. (Ed.) Pharmacoeconomics: From Theory to Practice. CRC Press
2020
Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
OHE Research Paper
2020
Open source models in HEOR: benefits, challenges, and ISPOR members’ perceptions
ISPOR Educational Webinar
2020
Candidate bolt-ons for cognition and vision: qualitative findings from a development programme
EuroQol Descriptive System Working Group Virtual Meeting
2020
Paradigm shifts in health state valuation – what is the future of utilities for QALYs?
ISPOR Virtual Conference
2020
Development and qualitative testing of EQ-5D-5L bolt-ons for cognition and vision
EuroQol Early Career Researcher meeting, Prague
2020
Risk calculation engines, cost-effectiveness analysis, and Microsoft Excel: lessons from an intractable model
Health Economists’ Study Group, Newcastle University
2020
The impact of a digital sleep-improvement program on health care costs
Health Economists’ Study Group, Newcastle University
2019
How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
OHE Briefing
2019
Development of EQ-5D-5L bolt-ons for cognition and vision
ISPOR Europe, Copenhagen
2019
The impact of a digital sleep-improvement program on health care costs
ISPOR Europe, Copenhagen
2019
Drop dead: is anchoring at ‘dead’ a theoretical requirement in health state valuation?
Health Economists’ Study Group, University of York
2018
The Impact of New Medicines in the NHS: 70 Years of Innovation
OHE Consulting Report
2018
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
OHE Research Paper
2018
Barriers to Uptake of Minimal Access Surgery in the United Kingdom
OHE Consulting Report
2018
Drop dead: is anchoring at ‘dead’ a theoretical requirement in health state valuation?
EuroQol Group Scientific Plenary, Lisbon
2018
Optimising risk-based screening: the case of diabetic eye disease
Health Technology Assessment International, Vancouver
2018
Long-term evaluation of broad mental health interventions: a review
Health Technology Assessment International, Vancouver
2018
Building bridges not walls: can we develop sustainable and sharable cost-effectiveness models?
Health Technology Assessment International, Vancouver
2017
Putting the ‘extra’ in animal welfare: health maximisation for non-human animals
International Society for Economics and Social Sciences of Animal Health Inaugural Meeting, Aviemore
2017
Systematic review and meta-analysis of health state utility values for diabetic retinopathy: implications for model-based economic evaluation
Health Economists’ Study Group, University of Birmingham
2016
British Journal of General Practice
2016
The Lancet Psychiatry
2016
Child: Care, Health and Development
2016
Prosthetics and Orthotics International
2016
In: Round, J. (Ed.) Care at the End of Life: An Economic Perspective. Springer International Publishing
2016
PeerJ Preprints
2016
Risk-based screening for diabetic retinopathy: a model for individualisation
Third EuHEA PhD Student-Supervisor and Early Career Researcher Conference, Barcelona
2016
Microcosting diabetic eye screening: estimation of personal expense, attendance and health care resource use
European Association for the Study of Diabetes Eye Complications Study Group Annual Meeting, Manchester
2016
Health-related quality of life of people attending screening for diabetic retinopathy within a trial setting
European Association for the Study of Diabetes Eye Complications Study Group Annual Meeting, Manchester
2016
Individualised cost-effectiveness analysis in risk-based screening: practical and ethical?
Health Economists’ Study Group, University of Manchester
2015
The Mental Elf
2015
Family Practice
2015
Systematic Reviews
2015
Cost-effectiveness of a risk-based screening programme for diabetic retinopathy: a modelling approach
EASDec Annual Meeting, University of Turin
2015
Cost-effectiveness of a specialist depression service for resistant depression
Workshop on Costs and Assessment in Psychiatry, Venice
2015
Individualised cost-effectiveness analysis in risk-based screening: practical and ethical?
Personalised Medicine and Resource Allocation conference, University of Oxford
2014
British Journal of Occupational Therapy
2014
The Mental Elf
2013
Criminal Behaviour and Mental Health
2013
The European Journal of Health Economics
2013
Clinical Rehabilitation
2013
Generic preference based measures: how economists measure health benefit
Advances in Clinical Neuroscience and Rehabilitation
2013
The Mental Elf
2013
chrissampson.me
2013
The Lifestyle Elf
2013
The Academic Health Economists’ Blog
2013
The Academic Health Economists’ Blog
2013
The Mental Elf
2013
The relationship between individual risk and cost-effectiveness in screening interventions
Working paper
2013
Subjective well-being and generic preference-based measures of health: an empirical contribution
Health Economists’ Study Group, University of Exeter
2012
Economic evaluation of occupational therapy pre-discharge home visits for patients with a stroke: issues arising
The role of health economics in responding to the research needs of the health service through CLAHRCs, University of Birmingham
2012
Readiness for treatment in personality disorder
Health Services Research Network Symposium, Manchester
2012
Cost implications of treatment non-completion in personality disorder
East Midlands & South Yorkshire MHRN Annual Research Meeting, Nottingham
2012
Findings from the CLAHRC-NDL project: ‘The costs of non-completion in treatment for personality disorder’
Engaging People with Personality Difficulties in Services, University of Nottingham
2012
Optimising cost-effectiveness in risk-based screening programmes: a modelling approach
Health Economists’ Study Group and Collège des Économistes de la Santé Workshop, Aix en Provence
2011
Findings from the CLAHRC-NDL project: ‘The costs of non-completion in treatment for personality disorder’
Personality Difficulties Development Event, Lincolnshire Partnership NHS Foundation Trust
2011
The cost implications of non-completion: a Markov model
British and Irish Group for the Study of Personality Disorder, University of Oxford
No publications match the selected filters.